Network Meta-analysis of Chinese medical injections for heart failure.
10.19540/j.cnki.cjcmm.2018.0049
- Author:
Feng-Wen YANG
1
;
Jia-Han ZOU
2
;
Yuan WANG
2
;
Chong-Xiang SUN
2
;
Long GE
3
;
Jin-Hui TIAN
3
;
Jun-Hua ZHANG
1
Author Information
1. Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.
2. Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.
3. Evidence-based Medicine Center, Lanzhou University, Lanzhou 730000, China.
- Publication Type:Journal Article
- Keywords:
Chinese medical injection;
heart failure;
network Meta-analysis
- From:
China Journal of Chinese Materia Medica
2018;43(6):1247-1253
- CountryChina
- Language:Chinese
-
Abstract:
To assess the clinical efficacy of Chinese medical injection (CMI) for heart failure by using network Meta-analysis method. The relative randomized controlled trials (RCTs) of CMI for heart failure were retrieved from China National Knowledge Infrastructure (CNKI), WanFang Database, Chinese Biomedical Literature Database (SinoMed), PubMed, Cochrane Library and EMbase in July 2017. RCTs on the comparison of two kinds of CMIs for heart failure were included. Two researchers independently completed the literature screening, data extraction and quality evaluation according to the pre-determined inclusion and exclusion criteria, and the results were crossed checked. The data were analyzed by Win Bugs, and STATA software was used for plotting. Finally, 13 RCTs were included, involving 5 kinds of CMIs and 1 538 patients. According to the quality evaluation, the appropriate random dividing methods were reported in only two RCTs, double-blindness was used in only one RCT, and even none of the RCTs mentioned allocation concealment. Network Meta-analysis showed that Shenmai injection had the greatest effect in the clinical efficacy for patients with heart failure, which was followed by Shenfu Injection. However, Shenfu Injection was most effective in improving the patients' left ventricular ejection fraction (LVEF), which was followed by Shenmai Injection. Therefore, Shenfu Injection and Shenmai Injection had certain advantages in treating heart failure. However, due to the limited sample size and the poor literature quality, more studies were required to verify the strength of evidence. We suggest that further studies shall pay more attention to the improvement of the methodological quality, increase the follow-up period, and strengthen the observation of cardiovascular end points.
